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Abstract
Background: Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a
major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to
insufficient trafficking of specific T cells to tumors. A key requirement for efficient migration of cytotoxic T cells is
that they express chemokine receptors that match the chemokines produced by tumor or tumor-associated cells.
Methods: In this study, we investigated whether the in vivo tumor trafficking of activated T cells could be enhanced
by the expression of the chemokine receptor CX3CR1. Two human colorectal cancer cell lines were used to set up a
xenograft tumor model in immunodeficient mice; the NCI-H630, constitutively expressing the chemokine ligand
CX3CL1 (Fractalkine), and the RKO cell line, transduced to express CX3CL1.
Results: Human primary T cells were transduced with the receptor CX3CR1-eGFP. Upon in vivo adoptive transfer of
genetically modified CX3CR1-T cells in mice bearing NCI-H630 tumors, enhanced lymphocyte migration and tumor
trafficking were observed, compared to mice receiving Mock-T cells, indicating improved homing ability towards
ligand-expressing tumor cells. Furthermore, significant inhibition of tumor growth was found in mice receiving
modified CX3CR1-T cells. In contrast, tumors formed by RKO cells transduced with the ligand (RKO-CX3CL1) were not
affected, nor more infiltrated upon transfer of CX3CR1-T lymphocytes, likely because high levels of the chemokine were
shed by tumor cells in the systemic circulation, thus nullifying the blood-tissue chemokine gradient.
Conclusions: This study demonstrates that ectopic expression of CX3CR1 enhanced the homing of adoptively
transferred T cells towards CX3CL1-producing tumors, resulting in increased T cell infiltration in tumor tissues and
decreased tumor growth. Our results also establish that a correct chemokine gradient between the systemic circulation
and the tumor is an essential requirement in adoptive T-cell based immunotherapy to efficiently recruit T cell effectors
at the correct sites.
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Background
Cancer immunotherapy involves the harnessing of the
immune system to recognize and destroy tumor cells,
and is an increasingly growing area of research to combat
different types of cancer [1]. In the last decade, there has
been a tremendous increase in optimizing this approach
in order to make it a clinically feasible treatment. Adoptive
T cell therapy (ACT), one of the major modalities within
cancer immunotherapy, is a potentially powerful approach
to cancer treatment based on the infusion of tumor spe-
cific T cells [2–4].
ACT has multiple advantages over other forms of can-
cer immunotherapy, and relies on the transfer of ex vivo
activated and sometimes gene-engineered T cells, which
encounter and act against tumor antigens in patients,
mediating tumor regression in variety of cancer such as
melanoma [5], cervical cancer [6], lymphoma [7],
leukemia [8], bile duct cancer and neuroblastoma [9].
There are many ways to enhance and optimize the ACT
approach, such as isolating and re-educating tumor infil-
trated lymphocytes in IL-2-containing medium, or genet-
ically modifying T cells to express antigen-specific T cell
receptors (TCRs). T cells have been engineered to express
on their surface, chimeric antigen receptors (CARs) as
well as CARs including co-stimulatory molecules. Such
approaches have been effectively employed as a robust
treatment for cancer with greater number of patients
responding to therapy [10, 11].
However, one of the major limitations of ACT is the
failure to induce long-lasting responses, possibly because
an insufficient number of tumor-reactive T cells reach
the tumor [12]. It has been suggested that appropriate
trafficking of cytotoxic T lymphocytes to the tumor site
is a critical step to obtain anti-tumor responses, as the
presence of increased tumor-infiltrating lymphocytes
(TIL) has been reported to correlate with better clinical
outcomes [13, 14]. Of note, ACT appears successful
against hematological cancers, a result that underlies the
importance of proper T cell infiltration. T cells are recruited
from the circulation in a series of distinct processes, involv-
ing adhesion to endothelium, chemotaxis and extravasation
[15]. The critical steps of tissue penetration are dependent
on different factors such as expression of adhesion mole-
cules on endothelium and lymphocytes [16] and of chemo-
attractants produced by tumor tissues [17]. Considering the
major role of chemokines and their receptors in regulating
and directing the tissue trafficking of T lymphocytes, we ex-
plored the feasibility of transducing a chemokine receptor
in human T lymphocytes and investigated their tumor hom-
ing ability upon adoptive transfer in tumor-bearing mice.
Some studies have shown significantly higher infiltra-
tion of T cells with better migration potential when
modified to express relevant chemokine receptors on
their surface [18–26].
In this study, we focused on the chemokine Fractalk-
ine/CX3CL1, the unique member of the CX3-chemokine
subfamily, which exists as a membrane-bound molecule,
in addition to the cleaved soluble form. Fractalkine is
expressed in several types of cancer including pancreatic
[27], breast [28], gastric and colon cancer [29–32].
Through its specific receptor CX3CR1, it strongly induces
chemotaxis and migration of NK cells, Th1 lymphocytes
and macrophages [33, 34].
Here we show that the CX3CR1 receptor can be effi-
ciently transduced in human T cells; we have set up an
adoptive transfer model in NOD-scid IL-2Rgamma−/−
(NSG) mice bearing a human colorectal cancer cell line
constitutively expressing the ligand CX3CL1. Specific
enhanced recruitment of CX3CR1-T cells towards
CX3CL1-expressing tumor cells was observed, which
lead to reduced tumor growth. Thus, the re-direction of
T lymphocytes by chemokine receptors is feasible and
valuable, and could be exploited to maximize the cur-
rently available therapeutic resources.
Results
Expression of the chemokine Fractalkine/CX3CL1 in
human colo-rectal cancer specimens and cell lines
The chemokine Fractalkine/CX3CL1 is expressed in sev-
eral types of cancers and strongly induces chemotaxis and
migration of Th1 lymphocytes, NK cells and macrophages
[30, 33, 34]. We and others reported that this chemokine
is highly expressed in tumor cells of human colorectal
cancer (CRC) [30–32, 35, 36]. Figure 1a shows that from a
series of 171 CRC samples studied by immunohistochem-
istry, 83.6 % were positive or strongly positive for CX3CL1
and only 16.4 % had faint or negative immunostaining. Of
note, the normal non-involved colonic mucosa was
negative or weakly positive, as shown in Fig. 1b, which
also depicts a representative picture of a CX3CL1-
positive tumor sample.
Having determined that the majority of human CRC
samples express the ligand Fractalkine, we next selected
the most appropriate colorectal cancer cell lines to set
up a tumor model to perform in vivo adoptive transfer
experiments. It is known that in vitro established cancer
cell lines frequently lose the ability to produce specific
chemokines, as we reported for Fractalkine in pancreatic
cancer [37]. We examined the expression of CX3CL1 in
several colon cancer cell lines (Additional file 1: Figure
S1A and B). In RKO and HCT116 cells, the mRNA
levels were low and not inducible by IFN-γ and TNF-α,
while were constitutively detectable in NCI-H630 cells
and higher after stimulation (Additional file 1: Figure
S1A). We decided to use the native NCI-H630 cell line
and to transduce RKO cells with the cDNA of the
CX3CL1 gene. After transduction with the Fractalkine
gene fused with a Cherry vector, RKO cells did express
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high levels of mRNA levels, which were further induced
by IFN-γ and TNF-α stimulation (Additional file 1: Figure
S1B). Protein expression in NCI-H630 and RKO cells was
confirmed by immunofluorescence (Fig. 1c-d).
To set up the in vivo mouse model, NCI-H630, RKO-
Mock and RKO-CX3CL1 cells were inoculated s.c. in
immunodeficient NSG mice. Growth of RKO-CX3CL1
cells was identical to that of RKO-Mock cells, indicating
that the ectopic expression of CX3CL1 is not altering
tumor cell proliferation, as shown in Additional file 1:
Figure S1C. After three weeks, tumors were harvested to
measure Fractalkine production in tumor tissues. The
Fig. 1 Expression of Fractalkine/CX3CL1 in human colon cancer tissues and cell lines. a Immunostaining score of Fractalkine/CX3CL1 in 171
patients with colorectal cancer; numbers on top of bars define exact number of patients with a given score; b Immunostaining of Fractalkine/
CX3CL1 in human normal colonic mucosa (top) and in a representative human colon cancer tissue (bottom); c Immunofluorescence by confocal
microscopy of Fractalkine/CX3CL1 protein expression in NCI-H630 cells and d in RKO cells upon transduction of the Fractalkine cDNA (CX3CL1-cherry)
or mock-transduced (mock-cherry); e Quantification by ELISA of Fractalkine/CX3CL1 levels in the lysate of NCI-H630 tumors grown in NSG
mice, normal skin tissue was used as reference control; f ELISA of Fractalkine/CX3CL1 levels in tumor lysates obtained from RKO tumors
(RKO-MOCK and RKO-CX3CL1) grown in NSG mice
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ELISA assay demonstrated significantly higher amounts
of Fractalkine in the tumor lysates of NCI-H630 tumors,
as compared to skin lysates, used as a reference of
normal tissue (Fig. 1e); as expected, tumors formed
by RKO-CX3CL1 produced much higher amounts of
Fractalkine (Fig. 1f ).
Transduction of the receptor CX3CR1 in human T
lymphocytes enhances their migration towards its ligand
Fractalkine/CX3CL1
To optimize T cell trafficking into tumors producing the
chemokine Fractalkine, we transduced human T cells to
be adoptively transferred, with the chemokine receptor
CX3CR1.
The cDNA encoding CX3CR1-eGFP was cloned in the
retroviral plasmid pMP71 and CD3-activated human T
lymphocytes were transduced and further expanded in
IL-2-containing medium. Three days post viral transduc-
tion, cells were >80 % CD3+ with a mixture of CD4 and
CD8 lymphocytes (Additional file 2: Figure S2A); after
10 days, >90 % of cells were CD3+, indicating that the
vast majority of IL-2-expanded cells were T lympho-
cytes, and 80 % were CD8+ (Fig. 2a).
Expression of CX3CR1 and its cell surface localization
were assessed by flow cytometry using anti-human
CX3CR1 antibodies. The transduction efficiency in the
CD3+ T cell population, expressing both eGFP and
CX3CR1, was confirmed in the CD4+ subset (43 %) as
well as in CD8+ cells (44 %) (Fig. 2b). Expression of
Fig. 2 Transduction of the CX3CR1 receptor in human T cells and functional validation. a Population of CD3+ and of CD4+/CD8+ T cells post
retroviral transduction of eGFP/CX3CR1 or -eGFP gene after 10 days of in vitro culture with hIL-2 medium. b Representative flow cytometry plot
showing the transduction efficiency in eGFP or CX3CR1-eGFP in human T cells. Cells were gated on live cells followed by subsequent gating on
CD3, CD4 and CD8 positive T cells. c mRNA expression of CX3CR1 in transduced CD3/IL-2 activated human T cells (Bars, Triplicates +/−SEM *P < 0.05,
**P < 0.01 for difference between eGFP and CX3CR1-eGFP-T cells (Student’s t test). d Transwell migration assay of eGFP-T cells or CX3CR1-eGFP T cells
in response to different concentrations of rhCX3CL1, ****P < 0.0001, Two-way ANOVA
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CX3CR1 was also determined by quantitative real-time
PCR and found to be significantly higher in CX3CR1-
eGFP-transduced cells compared to control T lympho-
cytes transduced with eGFP vector alone (Fig. 2c). We
then performed a functional analysis of CX3CR1-
expressing T lymphocytes. The classical migration assay
was set up using recombinant human Fractalkine. The
results showed that CX3CR1-T lymphocytes had signifi-
cantly high and dose-dependent migration ability toward
Fractalkine, whereas T cells expressing only eGFP did
not show improved migration (Fig. 2d), confirming that
the transduced receptor was fully functional.
In vivo adoptive transfer of CX3CR1-transduced human T
lymphocytes results in enhanced migration towards
Fractalkine-expressing tumors
To address the homing and migration ability in vivo of
CX3CR1-T lymphocytes towards tumors expressing the
ligand, we performed adoptive T cell transfer experiments.
Mice were subcutaneously inoculated with NCI-H630
tumor cells and checked for tumor development; after
18 days, eGFP or CX3CR1-eGFP lymphocytes (3 × 106)
were transferred through tail vein injection. Mice re-
ceived transduced T lymphocytes every three-four days
(Fig. 3a). After three consecutive adoptive transfers, mice
were sacrificed and tumors harvested, digested enzymati-
cally and tumor-infiltrating lymphocytes (TIL) were ana-
lyzed by quantitative real-time PCR and by flow cytometry.
The representative cytometry analysis, illustrated in Fig. 3b,
shows high CD3+ and CX3CR1+ cells (within CD45+ gated
population) of mice receiving CX3CR1- transduced lym-
phocytes, compared to mice receiving eGFP-lymphocytes.
The proportion of CD8+ and CD4+ subpopulation
within CD3 positive TILs demonstrated that up to 85 %
of cells expressed CD8 (Fig. 3c); furthermore, a greater
proportion of CX3CR1+ T cells were present within the
CD3-gated population (Fig. 3d). The FACS analysis ob-
tained from four distinct mice showed significantly
higher infiltration of CD3+ and CX3CR1+ lymphocytes
in tumors of each mouse receiving CX3CR1-T lympho-
cytes, confirming their preferential tumor homing ability
(Fig. 3e). The Real-time quantitative PCR also demon-
strated significantly higher mRNA levels of T cell
markers (CD3, CD4, CD8 and CX3CR1) in tumors of
mice injected with CX3CR1-T cells (Fig. 4a). The presence
of TIL was also investigated by immuno-histochemistry in
tumor sections. We observed higher number of CD3 posi-
tive T cells in tumors of mice adoptively transferred with
CX3CR1-T cells compared to mice receiving eGFP- T cells
(Fig. 4b and c). Finally, the harvested NCI-H630 tumors
were measured and we found significant reduction in
tumor weight in mice injected with CX3CR1-T cells, indi-
cating effective anti-tumor activity of receptor positive T
lymphocytes (Fig. 4d).
We repeated the same type of experiment in mice
bearing tumors formed by RKO-CX3CL1 or RKO-Mock
cells. Surprisingly, after transfer of CX3CR1-T lympho-
cytes we did not observe any reduction in tumor weight
(Fig. 5a), nor were the tumors more infiltrated by T cells,
as evident from CD3 and CX3CR1 mRNA expression in
isolated tumor infiltrating cells (Fig. 5b, c). We suspected
that the chemokine Fractalkine could be possibly shed in
the circulation by RKO-CX3CL1 cells, thus abrogating
the chemokine gradient between tumor tissues and the
systemic circulation. Serum levels of Fractalkine in mice
bearing RKO-CX3CL1 tumors were in fact very high
(700 ng/ml) (Fig. 5d) while less than 1 ng/ml was de-
tected in the sera of mice bearing NCI-H630 tumors
(Fig. 5e). Furthermore, the lymphocyte analysis from
single cell suspension of lung tissues, after adoptive
transfer regimen, showed significantly more CD3 lym-
phocytes entrapped in the lungs of mice bearing
RKO-CX3CL1 tumors compared to RKO-Mock tu-
mors : 70 % CD3+ vs 50 %, (Additional file 3: Figure
S3A). Of note, no significant difference was observed
in the lung infiltrate of NCI-H630 tumors (Additional
file 3: Figure S3B).
This finding emphasizes the importance of an appro-
priate chemokine gradient to efficiently recruit lympho-
cytes towards the tumor site.
Overall, these results demonstrate that T cells express-
ing the chemokine receptor CX3CR1 show increased
homing towards tumors producing the specific ligand,
and highlight the critical issue of a gradient between per-
ipheral tissues and the tumor.
Discussion
Adoptive T cell transfer is increasingly used as anti-
cancer therapy but its efficacy is still to be optimized.
Several strategies have been pursued and introduced to
enhance the success of adoptive T cell immunotherapy.
Whereas most current approaches to genetically modify
tumor-specific T cells are aimed at enhancing T cell per-
sistence, tumor recognition or activation of innate im-
munity [38, 39], our study focused on the approach to
increase the homing of T cell to the tumor site.
There is strong evidence that chemokine ligands
expressed in the tumor micro-environment contribute
to the local recruitment of leukocytes [40–42]. The pro-
duction of specific chemokines has been related to the
presence of particular leukocyte subsets. For instance,
CCL5 and CXCL9 and CXCL10 contributed to the re-
cruitment of CD8 T cells in a mouse model of spontan-
eous melanoma [43]. Hong and colleagues have shown
that the chemotherapeutic drugs dacarbazine, temozolo-
mide, and cisplatin enhanced the expression of some
chemokines in melanoma patients, which in turn corre-
lated with improved immune control of tumors [44].
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Fig. 3 Adoptive transfer of CX3CR1-positive T cells to mice bearing NCI-H630 tumors. a Schematic representation of adoptive transfer of eGFP or
CX3CR1-eGFP expressing T cells in NSG mice implanted with NCI-H630 tumors. b Representative flow cytometry plot of explanted and disaggregated
tumors for the analysis of infiltrating human T lymphocytes (CD45 + CD3+/CX3CR1+) after adoptive transfer. Cells were gated on live cells, the plots
show the population of CD3/CD45 positive cells and CD45/CX3CR1 positive cells within the tumors. c Proportion of CD8+ and CD4+ subpopulation
within CD3 positive TILs. d Proportion of CX3CR1+ T cells in gated CD3+ tumor-infiltrating T cells (blue line: mice receiving CX3CR1-expressing T cells,
red line: mice receiving eGFP-T cells CD3). e Summary of percentage of total CD3+ (left) and CX3CR1+ (right) T cells in explanted tumors after adoptive
transfer, obtained from different mice (each dot represents a single mouse). +/−SEM **P < 0.01 for difference between control (eGFP) and test (CX3CR1)
group (Student’s t test)
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Vice versa, a decreased expression of chemoattractants
is associated with reduced infiltration of CD8 T cells and
tumor relapse following T cell therapy [45]. Notably, in a
subset of patients with melanoma metastases, lack of
chemoattractants coincides with limited migration of
CD8 T cells [43].
The introduction of chemokine receptors in genetically
engineered T cells has the potential to enhance the hom-
ing of adoptively transferred effector cells (T cells or NK
cells) leading to significantly improved tumor-targeting
[19]. Some studies have reported the transduction of che-
mokine receptors such as CXCR2, CXCR3, CCR2b or
photo-activatable CXCR4 [20, 22–24]. When gene-
engineered to express CXCR2, T cells displayed enhanced
trafficking towards tumor cells secreting the correspond-
ing chemokine CXCL1 [18]. Also, in xenograft tumor
models of mesothelioma and neuroblastoma, the genetic
introduction of CCR2 in T cells resulted in increased T
cell infiltration in tumors secreting CCL2 and was associ-
ated with significantly increased anti-tumor activity [21].
We chose to transduce the CX3CR1 receptor (among
many chemokine receptors) as several tumor types pro-
duce the unique ligand Fractalkine and, of importance,
this chemokine ligand is expressed as a membrane-bound
molecule, serving as an adhesion receptor [35, 36]. Fur-
thermore, Fractalkine is produced by activated endothelial
cells [46, 47], which may be of advantage for the recruit-
ment of adoptively transferred T cells from the blood
circulation to the tumor site. The CX3CR1 receptor is
mainly present in tissue resident macrophages (e.g. in the
intestinal mucosa), in a subset of NK cells, at low levels in
T cells, and preferentially expressed in activated Th1 lym-
phocytes [34]. Of note, we recently found in human colo-
rectal tumors, that T lymphocytes at the tumor front, as
Fig. 4 Analysis on tumor infiltrating human T cells after adoptive transfer to mice bearing NCI-H630 tumors. a mRNA expression of CD3, CD4, CD8 and
CX3CR1 (human specific primers) from tumors of mice receiving eGFP-T cells (white bars) or CX3CR1-eGFP T cells (black bars), triplicates +/−SEM. b
Immunohistochemical analysis of CD3 expression in paraffin embedded tumors after adoptive T cell transfer; c CD3 stain positive area quantified using
image pro analysis software. d Weight of tumors after adoptive transfer of eGFP/CX3CR1-eGFP lymphocytes in mice (6–7 mice per group). *P < 0.05,
**P < 0.01, ***P < 0.005, ****P < 0.001 for difference between eGFP and CX3CR1-eGFP expressing T lymphocytes (Student’s t test)
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well as within the tumor, do not express the CX3CR1 re-
ceptor and therefore cannot be recruited at tumor site, in
spite of ligand expression by cancer cells [31].
In the present study, transduction of CX3CR1 into
CD3/IL-2 activated T cells was achieved quite efficiently
and resulted in an appropriately located surface receptor
that was functionally active in migration assays in vitro.
The adoptive transfer of CX3CR1-transduced T cells in
tumor-bearing mice indeed resulted in improved homing
towards Fractalkine-expressing tumors. This was con-
firmed by mRNA, flow cytometry of human TIL in
mouse tumors, and by immunohistochemistry.
As a source of ligand-expressing tumor cells, we have
selected the human colorectal cell line NCI-H630 that
constitutively produces low levels of Fractalkine. In
parallel experiments we used also another tumor cell
line (RKO) transduced with Fractalkine and producing
very high levels of the chemokine, also as a shed soluble
ligand. Interestingly, under these conditions, the homing
of CX3CR1-T cells was not enhanced, compared to
eGFP-T cells. Mice bearing Fractalkine-transduced RKO
tumors had very high serum levels of circulating ligand,
which likely have interfered with the correct recruitment
of adoptively transferred T cells, while serum levels of
NCI-H630-formed tumors were negligible, indicating an
exclusively local expression. These findings are consistent
with the concept that localized expression of the chemo-
attractant, and hence a proper blood-tissue gradient, is a
crucial pre-requisite for the effective recruitment of adop-
tively transferred effectors from circulation to tumors.
Fig. 5 Adoptive transfer of CX3CR1-positive T cells to mice bearing RKO tumors over-expressing Fractalkine/CX3CL1. a Weight of RKO-Mock or
RKO-CX3CL1 tumors after adoptive transfer of GFP-T cells or CX3CR1-T cells. (b, c) mRNA expression of CD3 and CX3CR1 (human specific
primers) from RKO-Mock or RKO-CX3CL1 tumors receiving GFP-T cells or CX3CR1-T cells. d Quantification of Fractalkine in the blood
serum of mice bearing RKO-Mock or RKO-CX3CL1 tumors. e Quantification of Fractalkine in the serum of mice bearing NCI-H630 tumors
or in non-tumor-bearing mice
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In our study, we used polyclonal T cells generated by
CD3/IL-2 activation. Of note, we did observe slower
tumor growth in mice injected with CX3CR1-T cells;
this finding is of considerable importance because it in-
dicates that even T cell effectors with unknown tumor
specificity could be partially effective, if sufficient num-
bers reach the tumor.
The chemokine-transduction approach could be easily
applied to tumor-specific T cells generated by genetic
modification with specific T cell receptors, hopefully im-
proving their therapeutic efficacy [48]. This approach
may provide an important new avenue in “personalized
cancer therapy” taking advantage of defined chemokine
signatures within the tumor microenvironment and may
further benefit cancer patients undergoing ACT. Fur-
thermore, a targeted localized delivery of specific cyto-
toxic effector T cells may have the potential to prevent
common adverse effects associated to adoptive T cell im-
munotherapy, such as cytokine storm, and represents a
novel method to improve T cell cytotoxicity, infiltration
and ultimately anti-tumor efficacy.
Conclusions
Overall, our results demonstrate that T lymphocytes
engineered with the chemokine receptor CX3CR1 have
enhanced homing towards CX3CL1-producing tumors,
when adoptively transferred in vivo in mice. Increased T
cell trafficking and infiltration in tumor tissues resulted
in decreased tumor growth. Our results also established
the importance of a correct blood-tumor chemokine gra-
dient for the successful recruitment of adoptively trans-
ferred T cells.
Methods
Patients and tissue specimens
Patients included in this study underwent resective sur-
gery for colorectal cancer at the Clinical and Research
Institute Humanitas (Milan, Italy) from 1997 to 2003.
The study was approved by the Institute Ethical Com-
mittee, and written informed consent was obtained from
patients.
Animal experiment and adoptive transfer
6–8 weeks old female NSG (NOD/SCID/IL-2rg−/−) mice
(Jackson Laboratories) were used. Procedures involving
animals and their care confirmed to institutional guide-
lines in compliance with national (4D.L. N.116, G.U.,
suppl. 40, 18-2-1992) and international law and policies
(EEC Council Directive 2010/63/EU, OJ L 276/33,
22.09.2010; NIH Guide for the Care and Use of Labora-
tory Animals, U.S. National Research Council, 2011).
Mice (6–7 mice for each group) received subcutaneous
injection into the flanks with 3 × 106 of viable cells
(NCI-H630). For adoptive transfer experiments, 3 × 106
of transduced T lymphocytes were transferred in each
mouse through tail vein injection after 18 days of tumor
growth and for thrice at three days of interval. At last
mice were sacrificed and tumors were harvested. The ex-
periment was designed based on our previous study [49]
and pilot experiments.
Cells and reagents
HCT116, NCI-H630 and RKO cells were cultured in
RPMI 1640 medium supplemented with 10 % FBS,
2 mM Ultraglutamine and 100U/ml penicillin/strepto-
mycin (Lonza, BioWhittaker). The packaging cell line
Phoenix-A and HEK 293 T cells were cultured in
DMEM medium (Lonza, BioWhittaker) supplemented
with 10 % FBS, 2 mM Ultraglutamine and 100U/ml
penicillin/streptomycin. TNF-α and IFN-γ (Peprotech)
were used for in vitro stimulation of cell lines.
Monoclonal antibodies used in this study were as fol-
lows: anti-CD3 mAB OKT3 (EB16-0037-85, eBioscience),
PE-conjugated anti-human CX3CR1 (D070-5, MBL), allo-
phycocyanin (APC) conjugated anti-human CD3 (555342,
BD Biosciences), APC-Cy7 conjugated mouse anti-human
CD8 (557852, BD Biosciences), PerCP-Cy5.5-conjugated
anti-human CD3 (560835, BD Biosciences), APC con-
jugated anti-human CD45 (560973, BD Biosciences),
PE-Cy7 conjugated anti-human CD4 (557852, BD
Biosciences). Other reagents included RetroNectin
(T100-A, Takara); recombinant human IL-2 (202-IL,
R&D Biosystems); Collagenase Type I (C0130, Sigma);
DNAse I (D5025, Sigma), Hyaluronidase (H3506,
Sigma).
Cloning Fractalkine/Fractalkine receptor
To generate retroviral vector for fractalkine receptor,
CX3CR1-eGFP was amplified by PCR using human glio-
blastoma tumor sample as template (based on our previ-
ous study [50]) and cloned between the restriction sites
EcoRI and NotI into pMP71 retroviral vector (kind gift
from Dr. Wolfgang Uckert, MDC Berlin Germany).
Fractalkine gene was cloned and overexpressed in RKO
cell line using lentiviral mediated transduction as de-
scribed earlier [31].
Lymphocyte culture, activation, transduction and
expansion
PBMC from healthy donors were isolated by centrifuga-
tion through Ficoll-Isopaque (density = 1.077 g/cm3;
Amersham Pharmacia Biotech, Uppsala, Sweden). Human
T lymphocytes of healthy donors were activated with anti-
CD3 mAb and transduced with retrovirus harboring either
eGFP (Mock) or CX3CR1-eGFP transgenes. Moloney
murine leukemia retroviruses were produced by cocul-
tures of 293 T and Phoenix-A cells. Cells were calcium
phosphate transfected with transgenes, the helper vectors
Siddiqui et al. Journal for ImmunoTherapy of Cancer  (2016) 4:21 Page 9 of 12
pHIT60 MLV GAG/POL, and pCOLT-GALV ENV. The
transduction protocol of human T cells was optimized
and described previously. Transduced primary human T
cells were cultured in RPMI 1640 medium supplemented
with 25 mM HEPES, 200 mM L-glutamine, 10 %
human serum, antibiotics, and 360 IU/mL human
rIL-2 (Proleukin; Chiron, Amsterdam, The Netherlands)
and stimulated every 2 weeks with a mixture of irradiated
allogeneic feeder cells as described elsewhere [51, 52].
Flow cytometry
T Lymphocytes were washed and incubated in ice cold
washing buffer (phosphate-buffered saline (PBS) con-
taining 2 % FCS) with anti-CD3, anti-CD4, anti-CD45,
anti-CD8, and anti-CX3CR1-PE for 30 min. Cells were
then washed and fixed with 2 % PFA to acquire and ana-
lyzed with FACSCanto or LSR-II (BD Biosciences) and
FlowJo (Treestar) software.
ELISA
Equal number of cells (2 × 106) cells were seeded in a
monolayer fashion in a six well plate and allowed to
incubate in CO2 incubator at 37 °C. Supernatant was
collected post 24 h of incubation. ELISA for CX3CL1/
Fractalkine was performed using ELISA Kit (R&D)
according to manufacturer instructions. Tumor lysate
for ELISA was collected after mincing small tumor frag-
ments followed by incubation in lysis buffer and extrac-
tion of supernatant.
RT-PCR and Quantitative Real Time qPCR
Total RNA was isolated either from cells or tumors
using TRI reagent (Ambion) and quantified with nano-
drop. DNAse treatment (Turbo DNA-free kit, Ambion)
was performed to avoid genomic DNA contamination.
1 μg of total RNA was reverse-transcribed using the
High-Capacity cDNA Archive kit (Applied Biosystems).
cDNA was analyzed by SYBER Green based Quantitative
Real-Time PCR on ABI Prism® 7900HT Fast Real Time
PCR System (Applied Biosystem). 18S was used as in-
ternal control to normalize. All gene specific primers
were domestically designed. The sequences of the primer
pairs are as follows:
T cell migration
Lymphocyte migration assay was performed using 24-
well plate in triplicate by using 5.0 μm pore size positron
emission tomography (PET) membrane (BD Biosciences,
Bedford, MA). The upper chamber was loaded with
transduced T lymphocytes and the lower bottom cham-
ber was filled with culture medium supplemented with
different concentration of rhCX3CL1 (365-FR-025, R&D
Systems). After 18 h of incubation, the migrated cells to
the lower side of the inserts were harvested and
counted.
Immunofluorescence
NCI-H630 cell line were cultured on coverslips coated
with Poly-L-Lysine, washed in PBS and fixed in 4 % PFA
for 15’. After 2 washes in 2 % BSA in PBS, cells were in-
cubated with the primary antibody rabbit anti-human
CX3CL1 (Torrey Pines Biolabs), diluted in 2 % BSA,
0.1 % TritonX-100, 0.1 % glycine, 5 % Normal Goat
Serum in PBS. After 3 washes in washing buffer (0.2 %
BSA, 0.05 % Tween 20 in PBS), cells were incubated with
secondary antibody Alexa goat anti-rabbit 488 (Invitrogen)
for 1 h at room temperature. After 4 washes in washing
buffer, DAPI was used to stain nuclei. Coverslip was
mounted with Fluor PreserveTM Reagent (Calbiochem) and
the images were acquired with a laser scanning confocal
microscope (FluoView FV1000; Olympus). For image ana-
lysis, Imaris X64 7.0.2 Software (Bitplane, AG) was used.
Tumor digestion and isolation of TIL
Triple enzyme method was used to digest the tumor.
Briefly, harvested tumors were minced with scalpels into
very small fragments and mixed with 5 ml of HBSS con-
taining Collagenase (10 mg/ml), Hyaluronidase (1 mg/
ml) and DNase (200 U/ml) and incubated at 37° on stir
plate for 1–2 h. Tissue was further dissociated by pass-
ing through 100 μm nylon mesh filter unit into falcon
tubes to pellet and wash in fresh HBSS. Tumor infiltrat-
ing lymphocytes (TIL) were isolated based on their dens-
ity and collected at the interface between 40 % and 80 %
discontinuous Percoll gradient.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were deparaf-
finised and endogenous peroxidase was blocked with
18S (F-CGCCGCTAGAGGTGAAATTC; R-CTTTCGCTCTGGTCCGTCTT)
CD3 (F-GAGTTCGCCAGTCGAGAGCT; R-TCATCTTCTCGATCCTTGAGGG)
CD4 (F-CTTCTTCTGTGTCAGGTGCCG; R-AGGAGTCTCTTGATCTGAGACATCC)
CD8 (F-CTGAGCAACTCCATCATGTACTTCA; R-GTCGTGGTGGGCTTCGC)
CX3CR1 (F-GGGACTGTGTTCCTGTCCAT; R-GACACTCTTGGGCTTCTTGC)
CX3CL1 (F-TCTGCCATCTGACTGTCCTG; R-TGATGTTGCATTTCGTCACA)
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3 % hydrogen peroxide for 20 min at room temperature.
For CD3 staining, tumor sections were exposed to an
antigen retrieval procedure with 1 mM EDTA buffer. Re-
active sites were identified by exposure to Anti-Rat Poly-
mer HRP kit (Biocare Medical, CA USA) for 30 min at
room temperature. Immunoperoxidase staining was then
performed by using diaminobenzidine as a chromogen
(DAB+chromogenX-50, ChemMate, DakoCytomation,
Carpinteria, CA, USA). The slides were finally counter-
stained with haematoxylin (Harris Hematoxilyn, Dia-
Path, Microstain Division, Martinengo, Bergamo, Italy).
For quantitative evaluation, a computer-aided image
analysis software was used, able to discriminate the im-
munostained area on the basis of RGB color segmenta-
tion, and to calculate the percentage of immunoreactive
area as a fraction of the total area digitally captured. For
Fractalkine/CX3CL1 immunostaining, paraffin-blocks of
human tumors with a diagnosis of colorectal cancer
were obtained from the Humanitas Pathology archive
and stained as detailed in our previous study [31].
Statistical analysis
Prism software (v6.0a; Graphpad) was used to conduct
appropriate statistical procedures, as noted in the in-
dividual figure legends. P value <0.05 was considered
significant unless noted otherwise.
Additional files
Additional file 1: Figure S1. Constitutive and stimulated expression of
Fractalkine/CX3CL1 by human colorectal cancer cell lines. (A) Fractalkine/
CX3CL1 mRNA expression in different colorectal cancer cell lines cultured
with or without IFN-γ (1000U/ml) and TNF-α (50 ng/ml) for 24 h. (B)
Fractalkine/CX3CL1 expression in RKO cells transduced with the cDNA
of CX3CL1 (RKO-CX3CL1) or mock-transduced RKO-Mock. (C) Tumor growth
of RKO-Mock and RKO-CX3CL1 cells in NSG mice. (JPG 1379 kb)
Additional file 2: Figure S2. Transduction of human T lymphocytes
with eGFP/CX3CR1-eGFP gene. (A) Population of CD3+ and of CD4+/CD8
+ T cells post retroviral transduction of eGFP/CX3CR1 or -eGFP gene after
3 days of in vitro culture with hIL-2 medium. (JPG 1522 kb)
Additional file 3: Figure S3. Lymphocyte infiltration in the lungs of
tumor-bearing mice after adoptive transfer. Flow cytometry analysis of T
lymphocytes entrapped in the lungs of mice receiving adoptive transfer
of CX3CR1-T cells or GFP-T cells (3 mice per group). (A) Proportion of
CD3+ T lymphocytes among CD45+ cells in the disaggregated lungs
from mice bearing RKO-Mock or RKO-CX3CL1 tumors. (B) Proportion of
CD3+ T lymphocytes among CD45+ cells in the disaggregated lungs
from mice bearing NCI-H630 tumors. (JPG 1661 kb)
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infiltrating lymphocytes.
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